Head to Head Comparison: Lipella Pharmaceuticals (NASDAQ:LIPO) vs. Conduit Pharmaceuticals (NASDAQ:CDT)

Lipella Pharmaceuticals (NASDAQ:LIPO) and Conduit Pharmaceuticals (NASDAQ:CDT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.

Institutional and Insider Ownership

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 3.3% of Conduit Pharmaceuticals shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by insiders. Comparatively, 30.9% of Conduit Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Lipella Pharmaceuticals and Conduit Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipella Pharmaceuticals	$483,533.00	7.93	-$4.62 million	($4.25)	-0.75
Conduit Pharmaceuticals	N/A	N/A	-$540,000.00	N/A	N/A

Conduit Pharmaceuticals has lower revenue, but higher earnings than Lipella Pharmaceuticals.

Volatility and Risk

Lipella Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Conduit Pharmaceuticals has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Lipella Pharmaceuticals and Conduit Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipella Pharmaceuticals	0	0	1	0	3.00
Conduit Pharmaceuticals	0	0	0	1	4.00

Lipella Pharmaceuticals currently has a consensus target price of $16.00, indicating a potential upside of 404.73%. Given Lipella Pharmaceuticals’ higher possible upside, equities analysts clearly believe Lipella Pharmaceuticals is more favorable than Conduit Pharmaceuticals.

Profitability

This table compares Lipella Pharmaceuticals and Conduit Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-882.82%	-192.33%	-154.24%
Conduit Pharmaceuticals	N/A	N/A	-328.67%

About Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.